INMB Live signaler | Maksimer profitt med Getagraph.com

KJøP 113216 min ago

@ $14.06

Utstedt: 14 feb 2024 @ 21:50

Avkastning: -20.84%

Live Chart Being Loaded With Signals

Commentary (2 mai 2024 @ 22:00):

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease...

Stats
Dagens volum	130 528
Gjennomsnittsvolum	112 424
Markedsverdi	219.94M
EPS	$0 ( 2024-05-01 )
Neste inntjeningsdato	( $-0.530 ) 2024-05-31
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.66
ATR14	$0.0610 (0.55%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Moss David J	Buy	18 028	Common Stock
2024-04-19	Moss David J	Buy	18 028	Common Stock Warrants (right to buy)
2024-04-19	Tesi Raymond Joseph	Buy	18 028	Common Stock
2024-04-19	Tesi Raymond Joseph	Buy	18 028	Common Stock Warrants (right to buy)
2024-04-19	Lowdell Mark William	Buy	14 423	Common Stock

INSIDER POWER
97.72
Last 100 transactions
Buy: 3 367 309 \| Sell: 701 956

Volum Korrelasjon

Lang: -0.34 (neutral)

Kort: -0.45 (neutral)

Signal:(44.106) Neutral

INmune Bio Inc Korrelasjon

10 Mest positive korrelasjoner
ECPG	0.878
FIVN	0.859
TREE	0.855
IPDN	0.844
PIRS	0.843
CWBR	0.833
LCFY	0.83
STX	0.828
NXST	0.828
PALT	0.826

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

INmune Bio Inc Korrelasjon - Valuta/Råvare

-0.24
( neutral )

0.16
( neutral )

0.00
( neutral )

-0.19
( neutral )

-0.59
( weak negative )

0.36
( neutral )

INmune Bio Inc Økonomi

Annual	2023
Omsetning:	$155 000
Bruttogevinst:	$155 000 (100.00 %)
EPS:	$-1.670

FY	2023
Omsetning:	$155 000
Bruttogevinst:	$155 000 (100.00 %)
EPS:	$-1.670

FY	2022
Omsetning:	$374 000
Bruttogevinst:	$374 000 (100.00 %)
EPS:	$-1.600

FY	2021
Omsetning:	$-181 000
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.751

Financial Reports:

No articles found.

INmune Bio Inc

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.